Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Q1 Earnings Season Kicks Off Better than Expected
by Mark Vickery
We've got a long way to go, but some key regional banks have already reported and offered some relief to market participants.
Will Any Banks Show Signs of Stress? Global Week Ahead
by John Blank
In terms of macro data, the first snapshot of business activity in April (the PMIs) could provide a sense of how much pain the turmoil in the banking sector has inflicted on the world economy.
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Will Q1 Earnings Fuel a Rally in Dow ETF?
by Sweta Killa
As the index is closely tied to the cyclical sectors, the banking turmoil hit hard the Dow last month. Recession fears have added to the woes.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $164.32, marking a -0.5% move from the previous day.
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
by Zacks Equity Research
AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.
3 Sector ETFs to Play as Recession Fears Are on the Rise
by Yashwardhan Jain
With recession fears on the rise, look into some sectors that can shield from market volatility.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer
by Zacks Equity Research
J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.
Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates
by Kinjel Shah
J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.
Company News for Apr 6, 2023
by Zacks Equity Research
Companies in The News Are: CAG,FDX,AI,JNJ
Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits
by Zacks Equity Research
To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.
Company News for Apr 5, 2023
by Zacks Equity Research
Companies In The News Are: F, JNJ, GGB, AMC.
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $158.49, moving +1.05% from the previous trading session.
Merck (MRK), Seagen Drug Combo Gets FDA Nod for Bladder Cancer
by Zacks Equity Research
The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
by Zacks Equity Research
CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
by Zacks Equity Research
Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWD